MRNA — Moderna, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1682852 ·
Last close
$47.73
Market Cap
$18.94B
52W High
$59.48
52W Low
$43.68
ADV30
7,142,726
Next earnings
2026-07-31
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 389,000,000 -566,000,000 -1,388,000,000 -1,343,000,000 11,488,000,000 1,908,000,000 4,080,000,000
Dec 2025 676,000,000 224,000,000 -857,000,000 -826,000,000 12,338,000,000 2,595,000,000 3,688,000,000
Sep 2025 1,002,000,000 795,000,000 -260,000,000 -200,000,000 12,135,000,000 1,132,000,000 2,805,000,000
Jun 2025 137,000,000 18,000,000 -907,000,000 -825,000,000 12,010,000,000 1,279,000,000 2,611,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,466,000,000
Investing CF
$1,140,000,000
Financing CF
$606,000,000
CapEx
$-137,000,000
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-8.15
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$5,880,000,000
Inventory
$146,000,000
Receivables
$182,000,000
ST Investments
$3,297,000,000
EBIT TTM
$-3,112,000,000
Pretax Income TTM
$-3,138,000,000
Interest Exp TTM
$26,000,000
Analysts
19

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,224,999,936
EBITDA
$-2,299,000,064
Free Cash Flow
$-20,000,000
Enterprise Value
$14,980,026,368
Total Cash
$5,205,000,192
Total Debt
$1,298,000,000
Shares Out
396,786,259
Trailing EPS
$-8.14
Book Value
$18.66
ROE
-36.6%
ROA
-13.1%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,922,000,000 -3,074,000,000 -2,822,000,000 12,338,000,000 3,688,000,000 -1,873,000,000
Dec 2024 3,199,000,000 -3,945,000,000 -3,561,000,000 14,142,000,000 3,241,000,000 -3,004,000,000
Dec 2023 6,754,000,000 -4,239,000,000 -4,714,000,000 18,426,000,000 4,572,000,000 -3,118,000,000
Dec 2022 18,875,000,000 9,420,000,000 8,362,000,000 25,858,000,000 6,735,000,000 4,981,000,000
Dec 2021

TTM Snapshot

Revenues TTM
$12,026,000,000
NetIncome TTM
$759,000,000
OpCashFlow TTM
$0
Assets (Latest)
$14,142,000,000
Forward EPS
$-4.20

Max Pain — expiry 2026-06-12 (volume-derived — Yahoo OI feed degraded)

max pain strike: $47.50 · spot: $47.73 · call volume: 13,297 · put volume: 2,178
Expected Move to 2026-06-12: ±$2.96 (6.20%) — implied range $44.77$50.69 · ATM straddle on $47.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NBIX NEUROCRINE BIOSCIENCES INC $16.61B $165.24
BNTX BioNTech SE $21.87B $86.50
EXEL EXELIXIS, INC. $13.32B $52.99
BIIB BIOGEN INC. $29.39B $199.10
RVMD Revolution Medicines, Inc. $31.79B $149.55

News headlines (Yahoo Finance, 1h cache)

Does Moderna Need to Start Making Money?
2026-06-09 11:31 · Yahoo
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
2026-06-08 23:01 · Yahoo
3 ETFs For the Coming Genomics Revolution
2026-06-07 12:45 · Yahoo
How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases
2026-06-07 12:08 · Yahoo
Is Merck & Co. (MRK) One of the Best Cheap Stocks to Buy for Beginners?
2026-06-05 22:04 · Yahoo
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?
2026-06-05 15:30 · Yahoo
Why Is Moderna (MRNA) Stock Rocketing Higher Today
2026-06-05 02:45 · Yahoo
Moderna gets good news as it searches for life after Covid
2026-06-04 23:00 · Yahoo
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
2026-06-04 15:30 · Yahoo
Moderna Stock: Is MRNA Outperforming the Health Care Sector?
2026-06-04 12:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.